CD110 Polyclonal Antibody

Background:
MPL proto-oncogene, thrombopoietin receptor(MPL) Homo sapiens In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important

Alternative Names:
MPL, TPOR, Thrombopoietin receptor, TPO-R, Myeloproliferative leukemia protein, Proto-oncogene c-Mpl, CD110

Immunogen: Synthesized peptide derived from Thrombopoietin receptor at AA range: 321-370

Isotype: Rabbit

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

Observed band: 69,40

GeneID: MPL

Storage: -20°C/1 year

NOTE: For Research Use Only